Anzeige
Mehr »
Freitag, 01.05.2026 - Börsentäglich über 12.000 News
Öl bricht über $108 und Wedgemount dreht die Produktion genau jetzt wieder an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DLB7 | ISIN: CA88337V1004 | Ticker-Symbol: TTX
Düsseldorf
30.04.26 | 19:31
0,186 Euro
+5,08 % +0,009
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
THERALASE TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
THERALASE TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1910,21430.04.

Aktuelle News zur THERALASE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.04.Theralase Technologies Inc: Theralase 6,404,700-share private placement16
13.04.Theralase Technologies Inc: Theralase sees complete response in MIBC study2
13.04.Theralase Technologies Inc.: Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study163Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated to...
► Artikel lesen
10.04.Theralase Technologies Inc: Theralase closes $1.66M placement, $1M line of credit4
10.04.Theralase Technologies Inc.: Theralase(R) Closes $CAN 2.66 Million Financing314Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated to...
► Artikel lesen
THERALASE Aktie jetzt für 0€ handeln
10.03.Theralase Technologies Inc: Theralase Technologies closes $1.1-million financing3
10.03.Theralase Technologies Inc.: Theralase(R) Closes $1.1 M Non-Brokered Private Placement227Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated to...
► Artikel lesen
09.03.Theralase Technologies Inc: Theralase's Rutherrin data point to effectiveness1
09.03.Theralase Technologies Inc.: Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer191Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
02.03.Theralase Technologies Inc: Theralase's data point to enhanced cancer cell kill2
20.02.Theralase Technologies Inc.: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress659Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
17.02.Theralase Technologies Inc: Theralase to present bladder cancer data set at EAU261
10.02.Theralase Technologies Inc.: Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting251Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated...
► Artikel lesen
04.02.Theralase Technologies Inc: Theralase Technologies talks bladder cancer study results4
04.02.Theralase Technologies Inc.: Theralase(R) Provides Update on Bladder Cancer Clinical Study240Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated to...
► Artikel lesen
02.02.Theralase Technologies Inc: Theralase enrolls 90 patients in bladder cancer study9
12.01.Theralase Technologies Inc: Theralase, Ferring sign clinical development agreement12
12.01.XFRA TTX: WIEDERAUFNAHME/RESUMPTION243FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
12.01.Theralase and Ferring ink deal for new bladder cancer study7
12.01.Theralase Technologies Inc.: Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer295The collaborative clinical study will evaluate ADSTILADRIN (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive...
► Artikel lesen
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1